ConductScience.org, home

Paper25344762

Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.

Li H and 10 others. Cancer Chemother Pharmacol, 2014. Cited by 64 papers, by iCite.

Cite this record

ConductScience Library. Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression. Papers, record 25344762. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25344762

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.
PubMed
Journal
Cancer Chemother Pharmacol
PubMed
Year
2014
PubMed
Publication types
Comparative Study, Journal Article
PubMed
Citations, by iCite
64
iCite
Relative citation ratio, by iCite
1.76
iCite
Revised in PubMed
2023-09-19
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Li HHeyan
2Takayama KKoichi
3Wang SShuo
4Shiraishi YYoshimasa
5Gotanda KKeisuke
6Harada TTaishi
7Furuyama KKazuto
8Iwama EEiji
9Ieiri IIchiro
10Okamoto IIsamu
11Nakanishi YYoichi

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Carcinoma, Non-Small-Cell LungMajor topic
Lung NeoplasmsMajor topic
Vascular Endothelial Growth Factor AMajor topic
Animals
Antibodies, Monoclonal, Humanized
Bevacizumab
Cell Line, Tumor
Chromatography, High Pressure Liquid
Drug Resistance, Neoplasm
Enzyme-Linked Immunosorbent Assay
ErbB Receptors
Erlotinib Hydrochloride
Female
Humans
Mice
Mice, Inbred BALB C
Mice, Nude
Quinazolines
Xenograft Model Antitumor Assays

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT02704767Tarceva With or Without Apatinib in the Advanced Lung AdenocarcinomaBackground

Source ClinicalTrials.gov

Download CSV of trials

References41

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116079312FDA drug approval summary: erlotinib (Tarceva) tablets.Oncologist2005https://conductscience.org/library/papers/16079312PubMed
217602060FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.Oncologist2007https://conductscience.org/library/papers/17602060PubMed
310525095Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.J Pharmacol Exp Ther1999https://conductscience.org/library/papers/10525095PubMed
49354447Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.Cancer Res1997https://conductscience.org/library/papers/9354447PubMed
521296855Global cancer statistics.CA Cancer J Clin2011https://conductscience.org/library/papers/21296855PubMed
623594426Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.J Natl Cancer Inst2013https://conductscience.org/library/papers/23594426PubMed
717024232Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application.Cancer Gene Ther2007https://conductscience.org/library/papers/17024232PubMed
823468851EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital.PLoS One2013https://conductscience.org/library/papers/23468851PubMed
911506500Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors.Br J Cancer2001https://conductscience.org/library/papers/11506500PubMed
1021592673Targeted therapies for advanced non-small-cell lung cancer: current status and future implications.Cancer Treat Rev2012https://conductscience.org/library/papers/21592673PubMed
119377574Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.Cancer Res1997https://conductscience.org/library/papers/9377574PubMed
1223335047Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies.Int J Cancer2013https://conductscience.org/library/papers/23335047PubMed
1323335087Cancer statistics, 2013.CA Cancer J Clin2013https://conductscience.org/library/papers/23335087PubMed
1416362295Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.Cancer Chemother Pharmacol2006https://conductscience.org/library/papers/16362295PubMed
1517888036Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.Cancer Sci2007https://conductscience.org/library/papers/17888036PubMed
1623953842Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.Biomaterials2013https://conductscience.org/library/papers/23953842PubMed
1720729074
Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment.
Eur J Cancer2010https://conductscience.org/library/papers/20729074PubMed
1817374728The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.Mol Cancer Res2007https://conductscience.org/library/papers/17374728PubMed
1918596824VEGF-targeted therapy: mechanisms of anti-tumour activity.Nat Rev Cancer2008https://conductscience.org/library/papers/18596824PubMed
2021629292Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases.Nat Rev Drug Discov2011https://conductscience.org/library/papers/21629292PubMed

See all 41 referencesDownload CSV of references

Cited by46

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 64 citations.

PMIDTitleJournalYearIn PapersSource
41701619TRIPODD Enables Single-Cell Quantification of Therapeutic Efficacy.Mol Pharm2026https://conductscience.org/library/papers/41701619PubMed
40843133VEGF Signal Complexity Confers Resistance to Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.MedComm (2020)2025https://conductscience.org/library/papers/40843133PubMed
37873790Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis.Diseases2023https://conductscience.org/library/papers/37873790PubMed
37817767Pre-clinical lung squamous cell carcinoma mouse models to identify novel biomarkers and therapeutic interventions.Front Oncol2023https://conductscience.org/library/papers/37817767PubMed
37698765Modern therapies of nonsmall cell lung cancer.J Appl Genet2023https://conductscience.org/library/papers/37698765PubMed
37427337
A retrospective study of the efficacy of combined EGFR‑TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR‑TKI monotherapy for PD‑L1‑positive EGFR‑mutant non‑small cell lung cancer: North Japan Lung Cancer Study Group 2202.
Oncol Lett2023https://conductscience.org/library/papers/37427337PubMed
36945221Molecular docking analysis of VEGF with compounds from tomato.Bioinformation2022https://conductscience.org/library/papers/36945221PubMed
36567417CPSF4 promotes tumor-initiating phenotype by enhancing VEGF/NRP2/TAZ signaling in lung cancer.Med Oncol2022https://conductscience.org/library/papers/36567417PubMed
36523304The reversal of anti-HER2 resistance in advanced HER2-positive breast cancer using apatinib: two cases reports and literature review.Transl Cancer Res2022https://conductscience.org/library/papers/36523304PubMed
36140220Inflammatory Cytokine: An Attractive Target for Cancer Treatment.Biomedicines2022https://conductscience.org/library/papers/36140220PubMed
36002195[Research Progress of Angiogenesis Inhibitors Plus EGFR-TKI in EGFR-mutated Advanced Non-small Cell Lung Cancer].Zhongguo Fei Ai Za Zhi2022https://conductscience.org/library/papers/36002195PubMed
35813484VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment.Int J Biol Sci2022https://conductscience.org/library/papers/35813484PubMed
35743437
Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis.
J Clin Med2022https://conductscience.org/library/papers/35743437PubMed
35599308When to add anti-angiogenesis drugs to EGFR-mutated metastatic non-small cell lung cancer patients: a real-world study from Taiwan.BMC Cancer2022https://conductscience.org/library/papers/35599308PubMed
35116965Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma.Transl Cancer Res2019https://conductscience.org/library/papers/35116965PubMed
34855286Inhibitory effects of icotinib combined with antiangiogenic drugs in human non-small cell lung cancer xenograft models are better than single target drugs.Thorac Cancer2022https://conductscience.org/library/papers/34855286PubMed
34149898CXCR4 is a prognostic marker that inhibits the invasion and migration of gastric cancer by regulating VEGF expression.Oncol Lett2021https://conductscience.org/library/papers/34149898PubMed
33751366TRIPODD: a Novel Fluorescence Imaging Platform for In Situ Quantification of Drug Distribution and Therapeutic Response.Mol Imaging Biol2021https://conductscience.org/library/papers/33751366PubMed
33656275
Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells.
Thorac Cancer2021https://conductscience.org/library/papers/33656275PubMed
33506568ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non-small cell lung cancer.Thorac Cancer2021https://conductscience.org/library/papers/33506568PubMed

See all 46 cited byDownload CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
EREG2069PubTator's text mininghttps://conductscience.org/library/genes/2069NCBI Gene
KDR3791PubTator's text mininghttps://conductscience.org/library/genes/3791NCBI Gene
TXK7294PubTator's text mininghttps://conductscience.org/library/genes/7294NCBI Gene
VEGFA7422PubTator's text mininghttps://conductscience.org/library/genes/7422NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25344762

GET https://conductscience.org/api/papers/v1/25344762/references?page=2